In particular, PTP1B has been studied as potential therapeutic drug target in obesity and insulin resistance, since genetic interruption resulted in resistance to high-fat diet-induced insulin resistance and obesity [9,10]. This evidence concerns the gene PTPN1 and obesity disorder.